InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
Go back to InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting| InferX Corporation (NASDAQ: IFRX) | Delayed: 1.60 -0.08 (4.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.68 | 52 Week High | $0.05 | |||
| Open | $1.66 | 52 Week Low | $0.00 | |||
| Day High | $1.74 | P/E | N/A | |||
| Day Low | $1.60 | EPS | $0.00 | |||
| Volume | 773,735 | |||||
| InferX Corporation (NASDAQ: IFRX) | Delayed: 1.60 -0.08 (4.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.68 | 52 Week High | $0.05 | |||
| Open | $1.66 | 52 Week Low | $0.00 | |||
| Day High | $1.74 | P/E | N/A | |||
| Day Low | $1.60 | EPS | $0.00 | |||
| Volume | 773,735 | |||||
